/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

TriSalus Life Sciences Inc share price today is $4.11, up -1.44%. The stock opened at $4.095 against the previous close of $4.16, with an intraday high of $4.17 and low of $4.07.

style

pb-0

TriSalus Life Sciences Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$4.11 -0.0144(-1.44%) TLSI at 13 Mar 2026 03:31 PM Medical Devices

Lowest Today 4.07

Highest Today 4.17

Today’s Open 4.095

Prev. Close 4.16

52 Week High 7.95

52 Week Low 3.42

Day’s Range: Low 4.07 High 4.17

52-Week Range: Low 3.42 High 7.95

TriSalus Life Sciences Inc Institutional Holdings

TriSalus Life Sciences Inc Market Status

Strong Buy: 6

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

TriSalus Life Sciences Inc Fundamentals

Market Cap 248.82 M

PB Ratio 30.2854

PE Ratio 0.0

Enterprise Value 266.23 M

Total Assets 35.33 M

Volume 164265

TriSalus Life Sciences Inc Company Financials

Annual Revenue FY23:16016000 16.0M, FY22:12398000 12.4M, FY21:8401000 8.4M

Annual Profit FY23:13177000 13.2M, FY22:10140000 10.1M, FY21:7208000 7.2M

Annual Net worth FY23:-46071000 -46.1M, FY22:-47187000 -47.2M, FY21:-28845000 -28.8M

Quarterly Revenue Q3/2025:11566000 11.6M, Q2/2025:11213000 11.2M, Q1/2025:9167000 9.2M, Q3/2024:7349000 7.3M, Q2/2024:7364000 7.4M

Quarterly Profit Q3/2025:9660000 9.7M, Q2/2025:9411000 9.4M, Q1/2025:7672000 7.7M, Q3/2024:6345000 6.3M, Q2/2024:6452000 6.5M

Quarterly Net worth Q3/2025:-10811000 -10.8M, Q2/2025:-8288000 -8.3M, Q1/2025:-10375000 -10.4M, Q3/2024:-2399000 -2.4M, Q2/2024:-4332000 -4.3M

About TriSalus Life Sciences Inc & investment objective

Company Information TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Organisation Medical Devices

Employees 102

Industry Medical Devices

CEO Ms. Mary T. Szela B.S.N., M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*